Alivus Life Sciences Intrinsic Value
Alivus Life Sciences (ALIVUS) median intrinsic value is ₹1207.07 from 9 valuation models (range ₹330–₹2666), vs current price ₹1101.20 — +9.6% upside (Trading Near Calculated Value), margin of safety 8.8%. Read ALIVUS dividend track record for the complete payout history and dividend yield track record.
ALIVUS Valuation Methods Summary — DCF, Graham Number & P/E
Alivus Life Sciences intrinsic value across 9 models vs current price ₹1101.20 — upside/downside and value range per method. For current market price and key ratios, visit ALIVUS screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1011.78 | ₹809.42 - ₹1214.14 | -8.1% | EPS: ₹45.99, Sector P/E: 22x |
| Book Value Method | asset | ₹2665.60 | ₹2399.04 - ₹2932.16 | +142.1% | Book Value/Share: ₹1332.80, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹2041.60 | ₹1837.44 - ₹2245.76 | +85.4% | Revenue/Share: ₹1020.80, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2202.40 | ₹1982.16 - ₹2422.64 | +100.0% | EBITDA: ₹772.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1207.07 | ₹965.66 - ₹1448.48 | +9.6% | CF Growth: 0.3%, Discount: 15% |
| PEG Ratio Method | growth | ₹330.36 | ₹297.32 - ₹363.40 | -70.0% | EPS Growth: 6.6%, Fair P/E: 5.3x |
| Growth Adjusted P/E | growth | ₹705.46 | ₹634.91 - ₹776.01 | -35.9% | Revenue Growth: 4.5%, Adj P/E: 15.3x |
| ROE Based Valuation | profitability | ₹2202.40 | ₹1982.16 - ₹2422.64 | +100.0% | ROE: 17.0%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹1174.37 | ₹1056.93 - ₹1291.81 | +6.6% | EPS: ₹45.99, BVPS: ₹1332.80 |
ALIVUS Intrinsic Value vs Market Price — All Valuation Models
Alivus Life Sciences fair value range ₹330–₹2666 vs current market price ₹1101.20 across 9 valuation models. Analyse Alivus Life Sciences ownership pattern to track promoter, FII and institutional holdings.
ALIVUS Intrinsic Value Analysis — Undervalued or Overvalued?
Alivus Life Sciences median intrinsic value ₹1207.07, current price ₹1101.20 — Trading Near Calculated Value by 9.6%, margin of safety 8.8%.
What is the intrinsic value of ALIVUS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Alivus Life Sciences (ALIVUS) is ₹1207.07 (median value). With the current market price of ₹1101.20, this represents a +9.6% variance from our estimated fair value.
The valuation range spans from ₹330.36 to ₹2665.60, indicating ₹330.36 - ₹2665.60.
Is ALIVUS undervalued or overvalued?
Based on our multi-method analysis, Alivus Life Sciences (ALIVUS) appears to be trading near calculated value by approximately 9.6%.
ALIVUS Financial Health — Key Ratios vs Industry Benchmarks
Alivus Life Sciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 18.52 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 17.0% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 30.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.64x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
ALIVUS Cash Flow Quality — Operating & Free Cash Flow
Alivus Life Sciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹392 Cr | ₹84 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹414 Cr | ₹356 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹306 Cr | ₹233 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹598 Cr | ₹537 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹388 Cr | ₹354 Cr | Positive Free Cash Flow | 8/10 |